3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid - CAS 1429934-37-1

3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid is a polyethylene glycol (PEG)-based PROTAC linker that can be used in the synthesis of a series of PROTACs.

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula
C13H22O7
Molecular Weight
290.31

3,6,9,12,15-Pentaoxaoctadec-17-ynoic acid

    • Specification
      • Purity
        ≥95%
        Solubility
        Soluble in DMSO
        Appearance
        Pale Yellow Oily Matter
        Storage
        Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
        Shipping
        Room temperature in continental US; may vary elsewhere.
        IUPAC Name
        2-[2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid
        Synonyms
        Propargyl-PEG5-CH2CO2H;Propargyl-PEG5-CH2COOH; Propargyl-PEG4-CH2COOH; 3,6,9,12,15-Pentaoxaoctadec-17-yn-1-oic acid
    • Properties
      • Boiling Point
        413.7±40.0°C at 760 mmHg
        Density
        1.1±0.1 g/cm3
        InChI Key
        QOUMZZIPISUGKO-UHFFFAOYSA-N
        InChI
        InChI=1S/C13H22O7/c1-2-3-16-4-5-17-6-7-18-8-9-19-10-11-20-12-13(14)15/h1H,3-12H2,(H,14,15)
        Canonical SMILES
        C#CCOCCOCCOCCOCCOCC(=O)O
    • Reference Reading
      • 1. Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial
        Adam W Anz, Hillary A Plummer, Achraf Cohen, Peter A Everts, James R Andrews, Joshua G Hackel Am J Sports Med. 2022 Mar;50(3):618-629.doi: 10.1177/03635465211072554.
        Background:Autologous platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMC) are being used clinically as therapeutic agents for the treatment of knee osteoarthritis.Purpose/hypothesis:The purpose of this study was to compare the efficacy of BMC and PRP on pain and function in patients with knee osteoarthritis up to 24 months after injection. It was hypothesized that patients receiving BMC would have better sustained outcomes than those receiving PRP.Study design:Randomized controlled trial; Level of evidence, 2.
        2. Caffeine Improves Triathlon Performance: A Field Study in Males and Females
        Sunita Potgieter, Hattie H Wright, Carine Smith Int J Sport Nutr Exerc Metab. 2018 May 1;28(3):228-237.doi: 10.1123/ijsnem.2017-0165.Epub 2018 Jun 1.
        The ergogenic effect of caffeine on endurance exercise is commonly accepted. We aimed to elucidate realistically the effect of caffeine on triathlon event performance using a field study design, while allowing investigation into potential mechanisms at play. A double-blind, randomized, crossover field trial was conducted. Twenty-six triathletes (14 males and 12 females; mean ± SD: age = 37.8 ± 10.6 years, habitual caffeine intake = 413 ± 505 mg/day, percentage body fat = 14.5 ± 7.2%, and training/week = 12.8 ± 4.5 hr) participated in this study. Microencapsulated caffeine (6 mg/kg body weight) was supplemented 60 min pretrial. Performance data included time to completion, rating of perceived exertion, and profile of mood states. Blood samples taken before, during, and postrace were analyzed for cortisol, testosterone, and full blood count. Capillary blood lactate concentrations were assessed prerace, during transitions, and 3, 6, 9, 12, and 15 min after triathlons. Caffeine supplementation resulted in a 3.7% reduction in swim time (33.5 ± 7.0 vs. 34.8 ± 8.1 min, p < .05) and a 1.3% reduction in time to completion (149.6 ± 19.8 vs. 151.5 ± 18.6 min, p < .05) for the whole group. Gender differences and individual responses are also presented. Caffeine did not alter the rating of perceived exertion significantly, but better performance after caffeine supplementation suggests a central effect resulting in greater overall exercise intensity at the same rating of perceived exertion. Caffeine supplementation was associated with higher postexercise cortisol levels (665 ± 200 vs. 543 ± 169 nmol/L, p < .0001) and facilitated greater peak blood lactate accumulation (analysis of variance main effect, p < .05). We recommend that triathlon athletes with relatively low habitual caffeine intake may ingest 6 mg/kg body weight caffeine, 45-60 min before the start of Olympic-distance triathlon to improve their performance.
        3. The relationship of asprosin with β-hydroxybutyric acid and postpartum disorders in cows
        Mehmet Akif Kilinc, Ali Risvanli Acta Vet Hung. 2022 Jan 24.doi: 10.1556/004.2022.00002.Online ahead of print.
        The aim of the present study was to determine asprosin levels in cows, the relationship of this hormone with postpartum disorders and β-hydroxybutyric acid, and also the potential of asprosin to be a marker for postpartum diseases. The study was designed as a two-stage trial. In the first stage, blood asprosin and β-hydroxybutyric acid levels of 20 healthy Simmental cows aged 3-4 years were measured at the time of calving, and on days 3, 6, 9, 12 and 15 postpartum. In the second stage, 200 cows were divided into two groups: (1) healthy (n = 100) and (2) diseased (placental retention, hypocalcaemia, metritis, lameness, abomasal displacement, mastitis; n = 100); asprosin and β-hydroxybutyric acid concentrations of the blood were assessed on day 15 postpartum. In conclusion, the asprosin level was found to be at measurable levels in cows, and a negative correlation with β-hydroxybutyric acid was found. According to these findings, the data obtained from this study could be used for the prevention, control and treatment of some postpartum disorders associated with ketosis and for developing novel hypotheses concerning the actions of this hormone. It was concluded that further studies are required to reveal the associations between asprosin and postpartum disorders.
Bio Calculators
Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g
Related Products
BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Inquiry Basket